Israel's vaccine candidate to go for human trials from October-end
In news about COVID-19 and the race in developing a vaccine for the same, it has come to light that Israel’s vaccine candidate named ‘Brilife’ is to begin its human trials by the end of October, says an official press release. The vaccine candidate Brilife is being developed by the Israel Institute of Biological Research (IIBR) which was instituted in 1952 as part of the Israel Defence Forces’ Science Corps, and following which it became a civilian organisation. The Director of IIBR, Shmuel Shapira on Monday, unveiled the name of the proposed vaccine ‘Brilife’, which is a combination of the Hebrew word “Bri” (health) and “il” (the internet country code for Israel) and “life”.
Earlier, In May, Israel had announced that the IIBR, mandated to develop a vaccine for the coronavirus, had made a "significant breakthrough" by wrapping up the development phase of the antibody and moving to patent and mass-produce the potential treatment. Following this in August, Israel had announced that a vaccine for COVID-19 was already in the making but that it had to go through regulative processes that would commence with the trials on human after autumn. While it hasn’t been specified as to how long the human trials could take and by when the vaccine candidate Brilife would be ready for possible use.
Defence Minister Benny Gantz on October 19, during a visit to IIBR, described the process of the initiating of the human trials as a ‘very significant moment which is a source of national pride,’ bringing the country and the world great news.
The Defence Minister Benny Gantz during the visit reportedly said, “We are at a very significant moment. The staff has done fantastic work. If the process is successful, it will be huge news for the state of Israel and maybe for the world. I’d like to thank the entire staff of researchers and administrators at the IIBR. You are a source of national pride.”
IIBR Director, Shmuel Shapira during the Defence Minister’s visit on October 19, was quoted saying, “We set out nine months ago on February 2, and we are entering the final round at the end of October. We will continue to work for the health of the citizens of Israel as well as for the Israeli economy and society.”
The IIBR chief, during the minister's previous visit in August, had announced that "there is an excellent vaccine, but there are regulatory processes that the vaccine needs to go through. We will start safety and efficacy trials after the autumn holidays, but the product is in hand."
Read more related articles: